These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24460070)

  • 41. Radiobiological optimization comparison between pulse-dose-rate and high-dose-rate brachytherapy in patients with locally advanced cervical cancer.
    Annede P; Dumas I; Schernberg A; Tailleur A; Fumagalli I; Bockel S; Mignot F; Kissel M; Deutsch E; Haie-Meder C; Chargari C
    Brachytherapy; 2019; 18(3):370-377. PubMed ID: 30797698
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Two decades of high dose rate brachytherapy with external beam radiotherapy for prostate cancer.
    Åström L; Grusell E; Sandin F; Turesson I; Holmberg L
    Radiother Oncol; 2018 Apr; 127(1):81-87. PubMed ID: 29496280
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fast automated multi-criteria planning for HDR brachytherapy explored for prostate cancer.
    Breedveld S; Bennan ABA; Aluwini S; Schaart DR; Kolkman-Deurloo IK; Heijmen BJM
    Phys Med Biol; 2019 Oct; 64(20):205002. PubMed ID: 31530761
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy.
    Andrzejewski P; Kuess P; Knäusl B; Pinker K; Georg P; Knoth J; Berger D; Kirisits C; Goldner G; Helbich T; Pötter R; Georg D
    Radiother Oncol; 2015 Dec; 117(3):509-14. PubMed ID: 26349588
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantitative analysis of the factors which affect the interpatient organ-at-risk dose sparing variation in IMRT plans.
    Yuan L; Ge Y; Lee WR; Yin FF; Kirkpatrick JP; Wu QJ
    Med Phys; 2012 Nov; 39(11):6868-78. PubMed ID: 23127079
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Parametrial boosting in locally advanced cervical cancer: combined intracavitary/interstitial brachytherapy vs. intracavitary brachytherapy plus external beam radiotherapy.
    Mohamed S; Kallehauge J; Fokdal L; Lindegaard JC; Tanderup K
    Brachytherapy; 2015; 14(1):23-8. PubMed ID: 25455382
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Individualized Dose-Escalation of HDR Prostate Brachytherapy Implant to Decrease Required External Beam Radiation Dose: A Retrospective Feasibility Study.
    Dahn HM; Oliver PAK; Allen S; Cherpak A; Syme A; Patil N; Bowes D
    Adv Radiat Oncol; 2019; 4(4):641-648. PubMed ID: 31673657
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
    Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
    Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A method for a priori estimation of best feasible DVH for organs-at-risk: Validation for head and neck VMAT planning.
    Ahmed S; Nelms B; Gintz D; Caudell J; Zhang G; Moros EG; Feygelman V
    Med Phys; 2017 Oct; 44(10):5486-5497. PubMed ID: 28777469
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Under-utilisation of high-dose-rate brachytherapy boost in men with intermediate-high risk prostate cancer treated with external beam radiotherapy.
    Ong WL; Evans SM; Millar JL
    J Med Imaging Radiat Oncol; 2018 Apr; 62(2):256-261. PubMed ID: 29271056
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
    Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
    Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of three-dimensional radiation therapy planning tools and intraoperative ultrasound to evaluate high dose rate prostate brachytherapy implants.
    Kini VR; Edmundson GK; Vicini FA; Jaffray DA; Gustafson G; Martinez AA
    Int J Radiat Oncol Biol Phys; 1999 Feb; 43(3):571-8. PubMed ID: 10078639
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer.
    Makino T; Nakashima K; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Kumano T; Mizokami A
    Anticancer Res; 2019 Jan; 39(1):477-486. PubMed ID: 30591498
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer.
    Parzen JS; Ye H; Gustafson G; Yan D; Martinez A; Chen PY; Ghilezan M; Sebastian E; Limbacher A; Krauss DJ
    Radiother Oncol; 2020 Jun; 147():123-129. PubMed ID: 32276193
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Results of multiparametric transrectal ultrasound-based focal high-dose-rate dose escalation combined with supplementary external beam irradiation in intermediate- and high-risk localized prostate cancer patients.
    Kovács G; Müller K; Soror T; Melchert C; Guo X; Jocham D; Merseburger A
    Brachytherapy; 2017; 16(2):277-281. PubMed ID: 27964906
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience.
    Aluwini S; van Rooij PH; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1480-5. PubMed ID: 22285661
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of catheter displacement and anatomical variations on the dose distribution in MRI-guided focal HDR brachytherapy for prostate cancer.
    Maenhout M; van der Voort van Zyp JRN; Borot de Battisti M; Peters M; van Vulpen M; van den Bosch M; Moerland MA
    Brachytherapy; 2018; 17(1):68-77. PubMed ID: 28579419
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dose Summation Strategies for External Beam Radiation Therapy and Brachytherapy in Gynecologic Malignancy: A Review from the NRG Oncology and NCTN Medical Physics Subcommittees.
    Kim H; Lee YC; Benedict SH; Dyer B; Price M; Rong Y; Ravi A; Leung E; Beriwal S; Bernard ME; Mayadev J; Leif JRL; Xiao Y
    Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):999-1010. PubMed ID: 34147581
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acute patient-reported bowel quality of life and rectal bleeding with the combination of prostate external beam radiation, low-dose-rate brachytherapy boost, and SpaceOAR.
    Patel AK; Houser C; Benoit R; Smith RP; Beriwal S
    Brachytherapy; 2020; 19(4):477-483. PubMed ID: 32331976
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer.
    Kazi A; Godwin G; Simpson J; Sasso G
    BMC Cancer; 2010 Sep; 10():472. PubMed ID: 20809986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.